Sonoma Pharmaceuticals Gestion
Gestion contrôle des critères 3/4
Sonoma Pharmaceuticals' CEO is Amy Trombly, appointed in Sep 2019, has a tenure of 5.17 years. total yearly compensation is $726.54K, comprised of 44.7% salary and 55.3% bonuses, including company stock and options. directly owns 0.57% of the company’s shares, worth $21.42K. The average tenure of the management team and the board of directors is 3.1 years and 6.2 years respectively.
Informations clés
Amy Trombly
Directeur général
US$726.5k
Rémunération totale
| Pourcentage du salaire du PDG | 44.7% |
| Durée du mandat du directeur général | 5.2yrs |
| Propriété du PDG | 0.6% |
| Durée moyenne d'occupation des postes de direction | 3.1yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 6.2yrs |
Mises à jour récentes de la gestion
Recent updates
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Oct 17
Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower
Aug 27The Market Lifts Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Shares 75% But It Can Do More
Jul 12Investors Aren't Entirely Convinced By Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues
May 26Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99M
Aug 11Does Sonoma Pharmaceuticals (NASDAQ:SNOA) Have A Healthy Balance Sheet?
Sep 30Sonoma Pharmaceuticals reports FQ2 results
Nov 20Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$5m |
| Mar 31 2024 | US$727k | US$325k | -US$5m |
| Dec 31 2023 | n/a | n/a | -US$5m |
| Sep 30 2023 | n/a | n/a | -US$6m |
| Jun 30 2023 | n/a | n/a | -US$6m |
| Mar 31 2023 | US$560k | US$319k | -US$5m |
| Dec 31 2022 | n/a | n/a | -US$7m |
| Sep 30 2022 | n/a | n/a | -US$6m |
| Jun 30 2022 | n/a | n/a | -US$5m |
| Mar 31 2022 | US$643k | US$318k | -US$5m |
| Dec 31 2021 | n/a | n/a | -US$6m |
| Sep 30 2021 | n/a | n/a | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$5m |
| Mar 31 2021 | US$580k | US$300k | -US$5m |
| Dec 31 2020 | n/a | n/a | -US$3m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$5m |
| Mar 31 2020 | US$386k | US$153k | -US$4m |
Rémunération vs marché: Amy's total compensation ($USD726.54K) is about average for companies of similar size in the US market ($USD655.65K).
Rémunération et revenus: Amy's compensation has increased whilst the company is unprofitable.
PDG
Amy Trombly (56 yo)
5.2yrs
Titularisation
US$726,543
Compensation
Ms. Amy M. Trombly, Esq. has been Chief Executive Officer of Sonoma Pharmaceuticals, Inc. since September 27, 2019 and serves as its President and also serves as its Director since July 22, 2022. She is a...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 5.2yrs | US$726.54k | 0.57% $ 21.4k | |
| Chief Financial Officer | 1.6yrs | US$307.46k | 0.32% $ 11.8k | |
| Executive VP | 4.6yrs | US$658.67k | 0.58% $ 21.5k | |
| Controller | 1.3yrs | US$479.59k | 0.056% $ 2.1k |
3.1yrs
Durée moyenne de l'emploi
56yo
Âge moyen
Gestion expérimentée: SNOA's management team is considered experienced (3.1 years average tenure).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 2.3yrs | US$726.54k | 0.57% $ 21.4k | |
| Lead Independent Director | 11.7yrs | US$65.00k | 0.020% $ 755.9 | |
| Independent Director | 6.2yrs | US$47.50k | 0% $ 0 | |
| Independent Director | 17.6yrs | US$55.00k | 0.021% $ 800.7 | |
| Scientific Advisory Board | 1.3yrs | pas de données | pas de données |
6.2yrs
Durée moyenne de l'emploi
70.5yo
Âge moyen
Conseil d'administration expérimenté: SNOA's board of directors are considered experienced (6.2 years average tenure).